InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,613.36
(
-0.23%
)
US TECH 100
18,846.40
(
-0.88%
)
Dow Jones
41,533.66
(
0.34%
)
Brent Oil
72.19
(
1.12%
)
Bitcoin
57,765.86
(
-2.38%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 106608

Thursday, 01/30/2014 3:50:45 PM

Thursday, January 30, 2014 3:50:45 PM

Post# of 253125
NVO’s 2014 outlook underwhelms investors due in part to the threat from insulin FoB’s:

http://in.reuters.com/article/2014/01/30/us-novonordisk-results-idINBREA0T0M220140130

Novo Nordisk said on Thursday that it now expected sales to grow by 8-11 percent, below its average 13 percent growth rate over the last ten years. It forecast operating profit to grow by around 10 percent in local currencies.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up